Myriad Genetics Inc.
Latest From Myriad Genetics Inc.
Myriad, Merck & Astra Zeneca are expanding their partnership to develop the BRACAnalysis CDx prostate cancer test.
Results Recap: Support For Medtronic's 'Suspend Before Low' Insulin Pump Feature; Neuroelectrics' Starstim Treats Epilepsy Seizures
Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition, covering Feb. 22 through Feb. 28, includes published results from trials of Medtronic’s closed-loop artificial pancreas, Neuroelectrics’ nerve stimulation device to treat seizures, and Myriad’s companion diagnostic for pancreatic cancer.
The American Society of Breast Surgeons published new guidelines, recommending that genetic testing should be made available to all patients with a history of breast cancer. The new recommendations are not in line with existing guidelines made by the National Comprehensive Cancer Network.
The UK's National Institute for Health and Care Excellence (NICE) has included Myriad Genetics' EndoPredict in its recommendations for guiding adjuvant chemotherapy decisions for certain early breast cancer patients. The recommendation comes just a few weeks after new data showing the long-term prognostic value of the EndoPredict test was presented at the San Antonio Breast Cancer Symposium. The company is also making progress on its Vectra rheumatoid arthritis prognostic system with the publication of a large commercial cohort and several clinical studies on development of the adjusted Vectra score.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Myriad Genetics Inc.
- Senior Management
Mark C Capone, Pres. & CEO
R. Bryan Riggsbee, CFO
Jerry H Lanchbury, PhD, CSO
Johnathan M Lancaster, MD, PhD, CMO
Rishi Kacker, CTO
- Contact Info
Myriad Genetics Inc.
Phone: (801) 584-3600
320 Wakara Way
Salt Lake City, UT 84108
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.